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Osteomyelitis (OM) is a common complication of diabetic foot ulcers and/or diabetic foot infections. This
review article discusses the clinical presentation, diagnosis, and treatment of OM in the diabetic foot. Clinical
features that point to the possibility of OM include the presence of exposed bone in the depth of a diabetic
foot ulcer. Medical imaging studies include plain radiographs, magnetic resonance imaging, and bone
scintigraphy. A high index of suspicion is also required to make the diagnosis of OM in the diabetic foot
combined with clinical and radiological studies.
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‘O
steomyelitis’ (OM) is derived from three
Greek words: osteon, myelos, and itis. It refers
to the inflammation or infection of the bone
and bone marrow. It is frequently missed and under-
diagnosed in patients with diabetic foot problems. A high
index of clinical suspicion is required to make a diagnosis
since undiagnosed and untreated OM often leads to the
dreaded complication of limb amputation. The risk for
amputation in acute diabetic infections is four times
higher with OM than with soft tissue infection alone (1).
Also, the presence of OM requires a longer duration of
antibiotic therapy and a longer duration of hospital stay,
thereby raising the hospitalization costs specifically for
diabetic patients with OM.
The medical and surgical treatment of OM will also be
outlined in this review article. The key to the successful
treatment of OM in the diabetic foot is a combination
of antibiotic therapy and surgical procedures. The latter
may include surgical debridement with excision of the
osteomyelitic bone and/or minor amputations. In addi-
tion, stabilization of the foot is also an important factor
in the surgical management of OM in the diabetic
foot. Adjuncts to this treatment may include the use of
antibiotic-loaded cement spacers or beads after surgical
debridement. The role of conservative treatment of OM
in the diabetic foot with antibiotic therapy only is con-
troversial and this has been discussed in this paper.
However, in these cases surgery may need to be performed
for a relapse in the pathological entity.
The ultimate goal of treatment is to achieve limb
salvage wherever possible in the diabetic patient. How-
ever, in some cases major amputation such as below the
knee amputation may be warranted. Early diagnosis and
appropriate treatment is necessary to reduce the morbid-
ity and mortality of this disease.
Pathogenesis
Unlike hematogenous OM (seeding via bloodstream)
and direct inoculation (via open fractures), in the diabetic
foot, there is a contiguous spread of pathogens from
infection, complicating a diabetic foot ulcer to the bones
underlying these ulcers (2). Histologically, it is charac-
terized by the presence of leukocytes or inflammatory
cells, such as lymphocytes and plasma cells, and by the
presence of bone necrosis. OM is a common complica-
tion in the diabetic foot. Underlying OM is seen in 15%
of patients with diabetic foot ulcers (3), and in 20%
of patients with diabetic foot infections (4). The risk of
developing OM increases with ulcers larger than 2 cm
2 or
a diabetic foot ulcer with exposed bone or joint (5). The
most common sites of OM are in the forefoot (90%)
followed by the midfoot (5%) and hindfoot (5%) (610).
The most common bones involved are the weight-bearing
bones of the foot, particularly to what it is referred as
the ‘tripod of the foot’ that includes the first metatarsal
head, fifth metatarsal head, and the calcaneum (Fig. 1).
Other sites include the bones underlying lateral decubitus
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metatarsal and the calcaneum (11).
Clinical examination
A diabetic foot ulcer must be assessed meticulously in
terms of site, size, periphery, depth, content, and adjacent
skin environment. The foot and lower extremity must
also be assessed for the presence of any vasculopathy,
neuropathy, and extent of underlying infection. Peripheral
vascular disease may be present in 4565% of patients
with diabetic foot complications (68). Lower limb pulses
must be palpated and features of vascular disease need
to be assessed for skin color, temperature, and capillary
refill time. Basic non-invasive vascular studies should
also be conducted, including the anklebrachial and
toebrachial pressure indices. Duplex ultrasound can
help assess for significant arterial stenoses that may
warrant vascular intervention to enhance distal blood
flow (11). Peripheral neuropathy is seen in 88% of patients
with diabetic foot problems (7). This is frequently assessed
by using a Semmes Weinstein 5.07 gauge monofilament
to test 10 points on the foot for touch sensation. A score
of 7 or less indicates neuropathy and identifies a ‘foot at
risk’(11).Infectionisclinicallyassessedforbythepresence
of cardinal features of inflammation (redness, warmth,
swelling, pain) as well as ulcer discharge or wet gangrene.
The depth and extent of infection must be assessed since
it is progressing rapidly in the diabetic foot (11).
Laboratory and clinical findings
Laboratory findings that should be performed include
markers of infection [white blood cell (WBC) count,
C-reactive protein (CRP), erythrocyte sedimentation
rate (ESR)] and markers of healing (Hemoglobin A1C,
blood ureanitrogen/creatinine, albumin and hemoglobin).
M u t l u o g l ue ta l .( 1 )c o m p a r e dO Mw i t hs o f tt i s s u e
infection and found no difference in terms of WBC,
CRP, and renal function. However, ESRwas found to be
significantly higher in the OM group (90 vs. 70 mm/h)
and the mean hemoglobin to be lower in the OM group
(10.8 vs. 12.0). A meta-analysis by Butalia et al. (12)
showed that ESR 70 mm/h indicates an 11 fold greater
riskofOM.Michailetal.(13)found WBC,CRP,ESRand
Pro-Calcitonin to be significantly higher in OM compared
to soft tissue infection. However, it should be noted that
evidence is limited and no clear consensus exists on the
ability for laboratory tests to diagnose OM (2).
Clinical testing may include the probe-to-bone test
(PTB) that could be performed using a sterile, blunt metal
probe (Fig. 2). This test is easy to perform and evaluates
the ability to contact a bone in the depth of the ulcer.
Some authors advocate it is a reliable test to diagnose
OM(14,15).MoralesLozanoetal.(15)foundasensitivity
of 98% and a specificity of 79%. Aragon-Sanchez et al.
(14) found a sensitivity and specificity of 95 and 93%,
respectively.
A summary of studies on PTB tests is shown in
Table 1. There are variable results seen with sensitivity
ranging from 38 to 98% and specificity from 78 to 92%.
These studies have different populations and methodology.
Two studies assessed patients admitted to hospital
with diabetic foot infections. In one, the prevalence of
OM was 66% (16), and in the other it was 72% (14).
The three studies in the outpatient setting revealed OM
prevalence in 23.5% (17), 79.5% (15), and 12% (18).
Variation was also seen in mean ulcer duration in out-
patient studies: 44 weeks (15) and 25 weeks (18). Finally,
these studies did not all use the same reference markers
for confirmation of OM and some studies did not use
a standard reference marker (16, 17) for confirmation.
The PTB is a widely debated clinical sign (2) and more
evaluation is needed to determine the setting where the
Fig. 1. Diagram of weight-bearing tripod of the foot.
Fig. 2. Probe-to-bone test for osteomyelitis in the diabetic foot.
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test in the clinical setting where an expedited evaluation
for OM can be made before detailed imaging can be
performed.
Medical imaging for OM in the diabetic foot
Plain radiography
The sensitivity of plain films in the diagnosis of OM has
shown variable results. It is related to the chronicity of
the infection and at least 3050% bone loss is required
to show visible changes on plain radiographs and such
changes take at least 23 weeks to manifest (2). The
specificity of radiographs is also lowered due to difficulty
in distinguishing OM from Charcot neuroathropathy
joint disease (2). The most common OM changes that
may be seen on radiographs include osteopenia, perios-
teal thickening, cortical erosions, and new bone forma-
tion (19). Overall, the sensitivity and specificity are 54
and 68% respectively according to one meta-analysis (20).
Nevertheless, plain radiographs should be performed
initially as a baseline to assess the development and
presentation of OM in a bone (Fig. 3).
Magnetic resonance imaging
Magnetic resonance imaging (MRI) is presently consid-
ered the investigation of choice for diagnosing diabetic
foot OM (21). In OM, the loss of signal in T1-weighted
images and higher intensity on T2-weighted images can
reveal the pathology as early as 3 days after infection
(22). However, this bone edema can sometimes be difficult
to differentiate from non-infectious causes of edema
(23). The accuracy of MRI is challenged when Charcot
neuroarthropathy joint disease or recent surgical change
is present. Meta-analyses and reviews show that MRI is
probably the most useful imaging modality for assessing
OM with a sensitivity of about 90% and a specificity of
about 80% (12, 20, 24). MRI provides a good anato-
mical correlation but it is limited in terms of functional
correlation (Fig. 4).
Bone scintigraphy
Thethree-phasebonescanusingTechnetium-99m-Medronic
Acid Bisphosphonate provides a two-dimensional image
of areas in bone with active bone turnover. For diabetic
foot OM, bone scans have a sensitivity of 8090% but
a specificity of less than 50% (2527). The poor specificity
relatestoinabilityofthebonescantodistinguishOMfrom
other inflammatory or traumatic conditions involving
the bone, such as Charcot neuroarthropathy joint disease,
bone metastasis, gout, fracture, or even recent surgery
(28,29).Itmustalsobenotedthatitisdifficulttodelineate
the exact anatomical location or extent of infection with
a bone scan (Fig. 5).
Single photon emission computerized tomography
Single photon emission computerized tomography
(SPECT) combines bone scan with computerized tomo-
graphy to improve the anatomicalfunctional correlation
since it provides three-dimensional images of the foot.
However, the technology is still not widely available and
its diagnostic potential for diabetic foot OM is still being
researched (22).
Table 1. Results from probe-to-bone test in diagnosis of osteomyelitis
Study Year Number Setting Sensitivity Specificity PPV NPV
Grayson (16) 1995 76 Inpatients 66 85 89 56
Shone (17) 2006 104 Outpatients 38 91 53 85
Lavery (18) 2007 247 Outpatients 87 87 62 92
Morales (15) 2010 132 Outpatients 98 78 95 91
Aragon-Sanchez (14) 2011 356 Inpatients 97 92 97 93
Fig. 3. Plain radiograph. Evidence of cortical erosion of the ﬁfth
metatarsal head in a patient with osteomyelitis.
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Leukocytes can also be removed from the patient, tagged
with a radioactive tracer and re-infused into the patient
where they accumulate at an infected focus. WBC scans
have a sensitivity of at least 80% and a specificity of at
least 70% for diabetic foot OM (2527). WBC scanning
shows soft tissue infection and is not bone specific and
therefore correlation with the results of a bone scan is
useful with a sensitivity and specificity of 8090% (30).
This combination, however, would be time consuming,
expensive and perhaps best conducted when a MRI is
contraindicated.
Positron emission tomography
Only a few studies have been done using PET scan to
evaluate its diagnostic potential for OM in the diabetic
foot. PET scan images radioactive fluorine attached to
2-fluoro-2deoxy-D-glucose, which accumulates at sites of
increased intracellular glucose metabolism such as infec-
tion, inflammation, or malignancy. Its sensitivity ranges
from 80 to 100% while its specificity has been reported as
93% (26, 31). Combining PET with computerized tomo-
graphy improves the anatomical detail available (26).
Bone biopsy
The gold standard for the diagnosis of OM is histopatho-
logical and microbiological assessment of bone (3234).
The bone may be sampled percutaneously through a site
of non-infected skin, or intra-operatively during debride-
ment/amputation. Knowing the pathogens involved is
highly desirable especially when planning conservative
treatment. Histological features of OM are specific and
Fig. 4. MRI. T2-weighted image  irregular ‘whitening’ of
calcaneum suggests edema and osteomyelitis in a patient with
a calcaneal ulcer.
Fig. 5. Bone scan. Bone scan showing increased uptake localized to the base of the ﬁfth metatarsal, indicating osteomyelitis.
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teria to diagnose OM include the presence of sequestrum,
involucrum, necrotic bone, necrotic-inflammatory exu-
dates, fat necrosis, marrow edema, marrow fibrosis, bone
erosions, and cellular changes of acute or chronic inflam-
mation (36). However, some evidence suggests possi-
bility of subjectivity among pathologists and perhaps the
criteria for histological diagnosis have to be clarified (36).
Concurrent soft tissue infection may result in bacterial
contamination of bone sample and false positives are
possible and are still worthwhile as antibiotics can be
guided by sensitivities (32). Bone cultures are preferable
over soft tissue cultures (37). Successful antibiotic treat-
ment is more likely to occur when the choice of antibiotics
is guided by cultures from bone biopsy (38). If surgery
is not performed, bone cultures may be obtained via
percutaneous biopsy through an area of uninvolved skin
(39). The precision of this approach can be questioned
and Senneville et al. (27) found that after transcutane-
ous biopsies for culture, 1 in 4 ‘normal’ results were false
negatives. Needle aspiration when compared to transcu-
taneous bone biopsy was shown to be unreliable with
only33%concordancewithtranscutaneousbiopsyculture
results (40). Cultures from ulcer swabs may be useful for
predicting deep tissue cultures (41) but are only identical
to bone cultures between 12 and 30% of the time (12, 37,
42). Therefore, bone is best sampled under direct vision,
or a reasonably size percutaneous biopsy should be
undertaken to guide the choice of antibiotics.
Systemic antibiotic treatment
Staphylococcus aureus is the most common pathogen in
diabetic foot OM. However, it may be part of a poly-
microbial infection and frequent gram-negative bacterial
prevalence makes empirical antibiotic choices difficult
(32). Antibiotics may be less effective in treating areas
of necrotic bone and where biofilm formation impairs
penetration of antibiotics to the infective focus and
thus the standard surgical practice adopted is that chronic
OM must be treated by surgical removal of infected
and necrotic bone (21). However, successful treatment of
diabetic foot OM has been shown with antibiotic therapy
alone (6, 10, 31, 38). Recommended antibiotic regimes do
not have strong evidence. Guidelines from the Infectious
Diseases Society of America (IDSA) (32) suggested treat-
ment based on likely residual infection. They recommen-
ded antibiotics for 13 weeks for any residual soft tissue
infection, 46 weeks for residual but viable osteomyelitic
bone, or at least 3 months for non-operative cases.
Surgical treatment
The operative aim for management of diabetic foot OM
is to resect the affected bone and avoid leaving residual
disease (43). IDSA guidelines in 2012 recommended
effective surgical debridement followed by antibiotic
treatment, with duration dependent on clearance of the
infection (32). Surgical removal of an osteomyelitic digit
is likely to be more acceptable to a patient as it still
provides a satisfactory weight-bearing foot. For OM
involving the distal phalanx or middle phalanx of a
toe, disarticulation may be performed. However, for OM
involving the proximal phalanx or the metatarsal head,
a ray amputation is advised (Fig. 6) (11).
For OM of the calcaneum, partial or sub-total
calcanectomy (Fig. 7) may be required with a wound
direct closure or via a flap. This operation is less likely to
be acceptable to a patient than digital amputation as the
operation usually does not result in a satisfactory weight-
bearing foot (11).
Inadequate surgical resection is one of the causes
for re-operation. About a quarter of patients treated
for OM have been shown to require operations. This
was more likely if initial surgery was conservative or if
necrosis or ischemia were involved (8). The risk of below
the knee amputation was significantly higher with hind-
foot OM (50%), compared to forefoot OM (0.33%)
and midfoot OM (18.5%) (9). The additional benefit
of surgery is the access to bone biopsy for cultures
and histopathological analysis. One drawback of surgery
is the change of foot dynamics and anatomy. Partial
amputations and even conservative surgery can result in
biomechanical changes in the feet which may provoke
re-ulceration at a new site (44).
Foot deformity stabilization and antibiotic-
loaded cement spacers/beads
Stabilization of a foot deformity is critical for ulcer/wound
management in the diabetic foot and surgical correc-
tion is gaining favor over accommodative bracing (45).
Fig. 6. Showing bones removed during a second ray amputation
(second toe and partial resection of the second metatarsal).
Osteomyelitis in the diabetic foot
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and when there is concurrent OM, management is dif-
ficult. Pinzur et al. (45) showed that radical debride-
ment for OM, correction of deformity, and external
fixation is achievable with a healing and ambulation
rate of 83% after a single procedure and an overall limb
salvage of 96%.
Polymethylmethacrylate (PMMA) cement has been
loaded with antibiotics since the 1970s for use in ortho-
pedic surgery. In this technique, the antibiotic diffuses out
to local tissues where is reaches far higher local concen-
trations than can be obtained through systemic treatment
(46, 47). Antibiotics delivered systemically cannot attain
optimal levels in avascular sequestrae, and in the presence
of vasculopathy commonly seen in diabetic patients
(48, 49). The use of antibiotic impregnated beads following
debridement has shown successful outcomes in the treat-
ment of diabetic foot OM (50). Biodegradable options
for local antibiotic therapy are of interest that may soon
develop popularity (46, 47). Regardless of delivery,
after bony debridement these methods allow dead space
to be reduced while permitting residual infection to be
controlled with elution of drugs over several weeks,
which is desirable in the management of deep infection
(46, 47). More research, such as comparative trials would
be useful to prove that local antibiotics are more effec-
tive than systemic antibiotic therapy in terms of clinical
outcomes (2).
Conservative treatment (antibiotics-only) vs.
operative management of OM in the diabetic
foot
The efficacy of antibiotic-only treatment for diabetic
foot OM has been debated. In the last decade, a few
key studies have been done to support the treatment
of suspected diabetic foot OM with antibiotics alone
(6, 10, 31, 38). Bone biopsies were not routinely taken
for confirmation in these studies and antibiotics were
often empirically selected. Duration of antibiotics also
varied with minimum treatment of 6 weeks to 3 months.
Successful treatment was also defined differently, some
requiring complete ulcer healing and others requiring a
prolonged period without recurrence of infection. There-
fore, these studies are not fully comparable but report
that between 63 and 83% of patients may be treated with
systemic antibiotics alone (6, 10, 31, 38). As these studies
were predominantly based on outpatients, the extent of
infection may be less severe and conservative treatment
is more likely to succeed.
On the other hand, these studies show that between
13 and 28% of patients may worsen during treatment and
require early surgery (6, 10, 31). Recurrence of ulceration/
infection is common during or after successful treatment
as high as 30% (6, 10, 31), although about two thirds
of these recurrences may also be successfully controlled
conservatively rather than surgically (6, 31). One rando-
mized study (51) of 52 patients has compared antibiotic
and surgical treatment. Either a tailored antibiotic plan
was used for 90 days of ulcer healing or conservative
surgery was done followed by 10 days of antibiotics.
There was no statistical difference in time to ulcer/wound
healing between the surgical group (6 weeks) and the
antibiotic group (7 weeks) (51). This small trial did not
histologically confirm OM in the antibiotic group. The
authors also excluded those patients with severe infec-
tions, vasculopathy, renal failure or involvement of the
midfoot/hindfoot. Thus, their conclusions are only ap-
plicable to the healthier diabetic patients with forefoot
involvement.
Some cases where antibiotics may be suitable for
treatment of OM in the diabetic may include patient’s
own decision, patient unfit for surgery, infection involving
a small area of the forefoot or if the extent of surgery
requiredwould causesignificant destabilizationofthefoot
(andtheaimislimbsalvage)(52).Surgeryisrecommended
where the infection is multi-resistant or where there is
a non-reversible ischemia, as systemic antibiotics would
be of questionable efficacy. A non-salvageable limb will
require a proximal amputation (52).
Conclusion
OM is a common complication of a diabetic foot ulcer or
diabetic foot infection. A high index of clinical suspicion
is required for diagnosis. Useful radiological studies
include a combination of plain radiographs, bone scans,
and MRI. Bone specimen should be sent for culture and
sensitivity and histological studies. The key to surgical
treatment of chronic OM in the diabetic foot is excision
of the bone involved. Inadequate removal may lead to re-
operation. In the recent years, however, some studies and
one randomized control trial have shown that systemic
antibiotics can be used long term to treat OM avoiding
the need for amputation. Although a subset of these
patients will eventually require surgery, it may be feasible
to consider systemic antibiotics in the appropriate group
of patients based on bone cultures. However, surgery can
Fig. 7. Diagram showing the bone resection for partial
calcanectomy.
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use of antibiotic-loaded cement spacers/beads. Patients
with diabetic foot OM should be appropriately coun-
seled regarding their options and medically optimized to
ensure best outcomes with the treatment offered.
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